Sources / A regulatory filing

23andMe Holding Co., exhibit 99.1 to Form 8-K (SEC), 10 February 2022

3 records were read from this source, dated 10 Feb 2022 to 11 Oct 2026.

Open it on sec.gov

Its permanent copy is being made in the Wayback Machine.

Last checked 19 Oct 2026

What was read from it

Records read from this source
Record	Kind	As stated	Dated
A fifth year of GSK's exclusive drug-target discovery period on 23andMe's genetic and health survey database (one further exclusive year, paid by GSK)	Price observation	a one-time payment of $50 million for one further year of the exclusive period	10 Feb 2022
Price exclusivity by what it covers: sole distribution earns a little more, sole use by one buyer earns a multiple	Negotiation lever	What exclusivity is worth depends on what it covers. Where it means sole distribution…	10 Sep 2026
Exclusivity and exclusivity windows	Licence term	Offer exclusivity only for a defined field and a defined window, and charge a multiple…	11 Oct 2026

A fifth year of GSK's exclusive drug-target discovery period on 23andMe's genetic and health survey database (one further exclusive year, paid by GSK)
Kind
Price observation
As stated
a one-time payment of $50 million for one further year of the exclusive period
Dated
10 Feb 2022
Price exclusivity by what it covers: sole distribution earns a little more, sole use by one buyer earns a multiple
Kind
Negotiation lever
As stated
What exclusivity is worth depends on what it covers. Where it means sole distribution…
Dated
10 Sep 2026
Exclusivity and exclusivity windows
Kind
Licence term
As stated
Offer exclusivity only for a defined field and a defined window, and charge a multiple…
Dated
11 Oct 2026

Figures it feeds

23andMe Holding Co., exhibit 99.1 to Form 8-K (SEC), 10 February 2022: what was read… | AIData.Broker